leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 14:03:25 - browse：84249

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Chris Christie meets with Zelenskyy during Ukraine trip

WSS

How to ethically and practically extend health care to all

Pharma showers House GOP doctor with campaign cash

2 officers injured in shooting in Orlando, police say

1 dead, 9 hurt in July 4th fireworks explosion

Heart disease in astronauts blamed on cosmic radiation

EU climate chief is concerned over the expansion of the coal industry in China

hotspot

leisure time

focus

Hepatitis C has a cure — but many Americans still lack access to it

H.R. 3 is the wrong path to lower drug costs

Activists slam private health insurers over coverage restrictions

'Null' research findings aren't empty of meaning. Let's publish them

Sports medicine is finally prioritizing gender equality

How to ethically and practically extend health care to all

Heart attack and stroke risk calculators need revising

When waiting feels immoral: Empathy in the emergency department

Affirmative action in medical school literally saved lives

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

explore

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

A timeline of the missing Titanic tourist submersible

Physicians aren't 'burning out.' They're suffering from moral injury

4 dead, 2 in stable condition in Philadelphia shooting: Police

The cancer stories no one wants to hear

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Wikipedia

focus

knowledge

Wikipedia